Advertisement

200 Years after Jenner: The Search for a Cancer Vaccine

  • Willem W. Overwijk
  • Steven A. Rosenberg
Chapter

Abstract

Biologic therapy of cancer can be defined as a treatment that acts primarily through defense mechanisms or by the administration of natural mammalian substances. Two important questions emerge when considering using the body’s immune defenses to treat cancer.

Keywords

Tumor Antigen Metastatic Melanoma Cancer Vaccine Recombinant Vaccinia Virus Melanoma Antigen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rosenberg, S.A., J.C. Yang, S.L. Topalian, D.J. Schwartzentruber, J.S. Weber, D.R. Parkinson, CA. Seipp, J.H. Einhorn, and D.E. White. 1994. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907.PubMedCrossRefGoogle Scholar
  2. 2.
    Muul, L.M. 1987. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J.Immunol 755:989.Google Scholar
  3. 3.
    Rosenberg, S.A. 1990. Adoptive immunotherapy for cancer. Sci.Am. 262:62.PubMedCrossRefGoogle Scholar
  4. 4.
    Kawakami, Y., S. Eliyahu, C.H. Delgado, P.F. Robbins, K. Sakaguchi, E. Appella, J.R. Yannelli, G.J. Adema, T. Miki, and S.A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc.Natl.AcadSci.U.S.A. 91:6458.CrossRefGoogle Scholar
  5. 5.
    Rosenberg, S.A. 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol.Today 18:175.PubMedCrossRefGoogle Scholar
  6. 6.
    Kawakami, Y., S. Eliyahu, C.H. Delgado, P.F. Robbins, L. Rivoltini, S.L. Topalian, T. Miki, and S.A. Rosenberg. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc.Natl.Acad.SciU.S.A. 91 CrossRefGoogle Scholar
  7. 7.
    Rosenberg, S.A. and D.E. White. 1996. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J.Immunother.Emphasis. Tumor Immunol. 79:81.CrossRefGoogle Scholar
  8. 8.
    Overwijk, W.W., D.S. Lee, D.R. Surman, K.R. Irvine, C.E. Touloukian, C.C. Chan, M.W. Carroll, B. Moss, S.A. Rosenberg, and N.P. Restifo. 1999. Vaccination with a recombinant vaccinia virus encoding a “self antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes. Proc.Natl.AcadSci.U.S.A. 96:2982.CrossRefGoogle Scholar
  9. 9.
    Boon, T., P.G. Coulie, and D.E. Van. 1997. Tumor antigens recognized by T cells. Immunol.Today 18:261.CrossRefGoogle Scholar
  10. 10.
    Rosenberg, S.A. 1999. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 10:281.PubMedCrossRefGoogle Scholar
  11. 11.
    Tsang, K.Y., S. Zaremba, CA. Nieroda, M.Z. Zhu, J.M. Hamilton, and J. Schlom. 1995. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J.Natl.Cancer Inst. 87:982.PubMedCrossRefGoogle Scholar
  12. 12.
    Jager, E., Y.T. Chen, J.W. Drijfhout, J. Karbach, M. Ringhoffer, D. Jager, M. Arand H. Wada, Y. Noguchi, E. Stockert, L.J. Old, and A. Knuth. 1998. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J.Exp.Med. 187:265PubMedCrossRefGoogle Scholar
  13. 13.
    Robbins, P.F., M. el-Gamil, Y.F. Li, Y. Kawakami, D. Loftus, E. Appella, and S.A. Rosenberg. 1996. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J.Exp.Med. 183:1185.PubMedCrossRefGoogle Scholar
  14. 14.
    Morin, P.J., A.B. Sparks, V. Korinek, N. Barker, H. Clevers, B. Vogelstein, and K.W. Kinzler. 1997. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275:1787.PubMedCrossRefGoogle Scholar
  15. 15.
    Rubinfeld, B., P. Robbins, M. ei-Gamil, I. Albert, E. Porfiri, and P. Polakis. 1997. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275:1790.Google Scholar
  16. 16.
    Overwijk, W.W., A. Tsung, K.R. Irvine, M.R. Parkhurst, T.J. Goletz, K. Tsung, M.W. Carroll, C. Liu, B. Moss, S.A. Rosenberg, and N.P. Restifo. 1998. gp100/pmel 17 is a murine tumor rejection antigen: induction of “self”-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J.Exp.Med 188:211.CrossRefGoogle Scholar
  17. 17.
    Parkhurst, M.R., M.L. Salgaller, S. Southwood, P.F. Robbins, A. Sette, S.A. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J.Immunol. 757:2539.Google Scholar
  18. 18.
    Cormier, J.N., M.L. Salgaller, T. Prevette, K.C. Barracchini, L. Rivoltini, N.P. Restifo, S.A. Rosenberg, and F.M. Marincola. 1997. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J.Sci.Am. 5:37.Google Scholar
  19. 19.
    Salgaller, M.L., F.M. Marincola, J.N. Cormier, and S.A. Rosenberg. 1996. Immunization against epitopes in the human melanoma antigen gp 100 following patient immunization with synthetic peptides. Cancer Res. 56:4149.Google Scholar
  20. 20.
    Rosenberg, S.A., J.C. Yang, D.J. Schwartzentruber, P. Hwu, F. Marincola, S.L. Topalian, N.P. Restifo, M.E. Dudley, S.L. Schwarz, P.J. Spiess, J.R. Wunderlich, M.R. Parkhurst, Y. Kawakami, C.A. Seipp, J.H. Einhorn, and D.E. White. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat.Med. 4:321.PubMedCrossRefGoogle Scholar
  21. 21.
    Rosenberg, S.A., Y. Zhai, J.C. Yang, D.J. Schwartzentruber, P. Hwu, F.M. Marincola, S.L. Topalian, N.P. Restifo, C.A. Seipp, J.H. Einhorn, B. Roberts, and D.E. White. 1998. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp 100 melanoma antigens. J.Natl. Cancer Inst. 90 PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2000

Authors and Affiliations

  • Willem W. Overwijk
    • 1
  • Steven A. Rosenberg
    • 1
  1. 1.Surgery Branch, National Cancer InsitituteNational Institute of HealthBethesdaUSA

Personalised recommendations